Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Ovarian Neoplasms

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 81 articles:
HTML format
Text format



Single Articles


    February 2020
  1. KOTSOPOULOS J, Narod SA
    Prophylactic salpingectomy for the prevention of ovarian cancer; who should we target?
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32916.
    PubMed     Text format     Abstract available


    January 2020
  2. HANNIBAL CG, Frederiksen K, Vang R, Kurman RJ, et al
    Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: a nationwide-based study.
    Int J Cancer. 2020 Jan 12. doi: 10.1002/ijc.32864.
    PubMed     Text format     Abstract available


  3. YOSHIHARA M, Kajiyama H, Yokoi A, Sugiyama M, et al
    Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
    Int J Cancer. 2020 Jan 6. doi: 10.1002/ijc.32854.
    PubMed     Text format     Abstract available


    December 2019
  4. RAMRAJ SK, Elayapillai SP, Pelikan RC, Zhao YD, et al
    Novel Ovarian Cancer Maintenance Therapy Targeted at Mortalin and Mutant p53.
    Int J Cancer. 2019 Dec 17. doi: 10.1002/ijc.32830.
    PubMed     Text format     Abstract available


  5. WOLF D, Fiegl H, Zeimet AG, Wieser V, et al
    High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.
    Int J Cancer. 2019 Dec 4. doi: 10.1002/ijc.32818.
    PubMed     Text format     Abstract available


    November 2019
  6. WANG T, Townsend MK, Simmons V, Terry KL, et al
    Pre- and Post- Diagnosis Smoking and Survival Following Diagnosis with Ovarian Cancer.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32773.
    PubMed     Text format     Abstract available


  7. SOKOLENKO AP, Bizin IV, Preobrazhenskaya EV, Gorodnova TV, et al
    Molecular Profiles of BRCA1-Associated Ovarian Cancer Treated by Platinum-Based Therapy: Analysis of Primary, Residual and Relapsed Tumours.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32776.
    PubMed     Text format     Abstract available


    October 2019
  8. KRATZER TB, Weinstein SJ, Albanes D, Mondul AM, et al
    Vitamin D Binding Protein and Risk of Renal Cell Carcinoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).
    Int J Cancer. 2019 Oct 29. doi: 10.1002/ijc.32758.
    PubMed     Text format     Abstract available


  9. LEE YJ, Kim D, Shim JE, Bae SJ, et al
    Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Int J Cancer. 2019 Oct 11. doi: 10.1002/ijc.32729.
    PubMed     Text format     Abstract available


  10. SIMIN J, Rulla MT, Callens S, Engstrand L, et al
    Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.
    Int J Cancer. 2019 Oct 4. doi: 10.1002/ijc.32706.
    PubMed     Text format     Abstract available


  11. QIU JJ, Lin XJ, Tang XY, Zheng TT, et al
    Long Noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32692.
    PubMed     Text format     Abstract available


    September 2019
  12. LINK T, Passek S, Wimberger P, Frank K, et al
    Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.
    Int J Cancer. 2019 Sep 11. doi: 10.1002/ijc.32676.
    PubMed     Text format     Abstract available


  13. LYU T, Jiang Y, Jia N, Che X, et al
    SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
    Int J Cancer. 2019 Sep 10. doi: 10.1002/ijc.32673.
    PubMed     Text format     Abstract available


  14. YI T, Feng Y, Sundaram R, Tie Y, et al
    Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Int J Cancer. 2019;145:1209-1220.
    PubMed     Text format     Abstract available


    August 2019
  15. MANICHAIKUL A, Peres LC, Wang XQ, Barnard ME, et al
    Identification of novel epithelial ovarian cancer loci in Women of African Ancestry.
    Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32653.
    PubMed     Text format     Abstract available


  16. RICE MS, Poole EM, Willett WC, Tworoger SS, et al
    Adult Dietary Fat Intake and Ovarian Cancer Risk.
    Int J Cancer. 2019 Aug 23. doi: 10.1002/ijc.32635.
    PubMed     Text format     Abstract available


  17. RAY-COQUARD I, Cibula D, Mirza MR, Reuss A, et al
    Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
    Int J Cancer. 2019 Aug 5. doi: 10.1002/ijc.32606.
    PubMed     Text format     Abstract available


    July 2019
  18. ZHU Q, Zhang J, Chen Y, Hu Q, et al
    Whole-Exome Sequencing Of Ovarian Cancer Families Uncovers Putative Predisposition Genes.
    Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32545.
    PubMed     Text format     Abstract available


    June 2019
  19. GRUNDY A, Ho V, Abrahamowicz M, Parent ME, et al
    Lifetime recreational moderate-to-vigorous physical activity and ovarian cancer risk: a case-control study.
    Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32513.
    PubMed     Text format     Abstract available


    May 2019
  20. KLEIBLOVA P, Stolarova L, Krizova K, Lhota F, et al
    Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32385.
    PubMed     Text format     Abstract available


    April 2019
  21. CABASAG CJ, Arnold M, Butler J, Inoue M, et al
    The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32322.
    PubMed     Text format     Abstract available


    March 2019
  22. NURMI A, Muranen TA, Pelttari LM, Kiiski JI, et al
    Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Int J Cancer. 2019 Mar 30. doi: 10.1002/ijc.32309.
    PubMed     Text format     Abstract available


  23. LI H, Zhang W, Niu C, Lin C, et al
    Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32293.
    PubMed     Text format     Abstract available


    February 2019

  24. Expression of Concern: "Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells" by Hua Yang, Lili He, Patricia Kruk, Santo V. Nicosia and Jin Q. Cheng.
    Int J Cancer. 2019 Feb 27. doi: 10.1002/ijc.32225.
    PubMed     Text format    


  25. HE Y, Gu Z, Zhu Q, Chen M, et al
    CA125 over-release behavior following a 75-gram oral glucose test as a predictive biomarker of multidrug resistance in patients with ovarian cancer.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32237.
    PubMed     Text format     Abstract available


    January 2019
  26. BHASKARAN SP, Chandratre K, Gupta H, Zhang L, et al
    Germline variation in BRCA1/2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
    Int J Cancer. 2019 Jan 31. doi: 10.1002/ijc.32176.
    PubMed     Text format     Abstract available


  27. TRABERT B, Michels KA, Anderson GL, Brinton LA, et al
    Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study.
    Int J Cancer. 2019 Jan 26. doi: 10.1002/ijc.32157.
    PubMed     Text format     Abstract available


  28. BRANDAO RD, Mensaert K, Lopez-Perolio I, Tserpelis D, et al
    Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
    Int J Cancer. 2019 Jan 8. doi: 10.1002/ijc.32114.
    PubMed     Text format     Abstract available


    December 2018
  29. FORTNER RT, Poole EM, Wentzensen NA, Trabert B, et al
    Ovarian cancer risk factors by tumor aggressiveness: an analysis from the Ovarian Cancer Cohort Consortium.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32075.
    PubMed     Text format     Abstract available


    November 2018
  30. KIM S, Wang M, Tyrer JP, Jensen A, et al
    A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants.
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.32029.
    PubMed     Text format     Abstract available


  31. SCHUBERT S, van Luttikhuizen JL, Auber B, Schmidt G, et al
    The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: high frequency of FANCM pathogenic variants.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31992.
    PubMed     Text format     Abstract available


    September 2018
  32. LIU Z, Zhang S, Hou F, Zhang C, et al
    Inhibition of Ca(2+) -activated chloride channel ANO1 suppresses ovarian cancer through inactivating PI3K/Akt signaling.
    Int J Cancer. 2018 Sep 22. doi: 10.1002/ijc.31887.
    PubMed     Text format     Abstract available


  33. MONDAL S, Roy D, Sarkar Bhattacharya S, Jin L, et al
    Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers.
    Int J Cancer. 2018 Sep 18. doi: 10.1002/ijc.31868.
    PubMed     Text format     Abstract available


  34. LI J, Wen WX, Eklund M, Kvist A, et al
    Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
    Int J Cancer. 2018 Sep 2. doi: 10.1002/ijc.31841.
    PubMed     Text format     Abstract available


    August 2018
  35. ZHANG C, Wang X, Anaya Y, Parodi L, et al
    Distinct Molecular Pathways in Ovarian Endometrioid Adenocarcinoma with Concurrent Endometriosis.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31768.
    PubMed     Text format     Abstract available


  36. JIN C, Liu Z, Li Y, Bu H, et al
    PCNA-associated factor P15(PAF) , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients.
    Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31800.
    PubMed     Text format     Abstract available


  37. LU X, Li Y, Xia B, Bai Y, et al
    Selection of small plasma peptides for the auxiliary diagnosis and prognosis of epithelial ovarian cancer by using UPLC/MS-based non-targeted and targeted analyses.
    Int J Cancer. 2018 Aug 16. doi: 10.1002/ijc.31807.
    PubMed     Text format     Abstract available


    July 2018
  38. AKINWUNMI B, Vitonis AF, Titus L, Terry KL, et al
    Statin Therapy and Association with Ovarian Cancer risk in the New England Case Control (NEC) Study.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31758.
    PubMed     Text format     Abstract available


  39. CHEN HJ, Huang RL, Liew PL, Su PH, et al
    GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31750.
    PubMed     Text format     Abstract available


  40. AUSTRIA T, Marion C, Yu V, Widschwendter M, et al
    Mechanism of cytokinesis failure in ovarian cystadenomas with defective brca1 and p53 pathways.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31659.
    PubMed     Text format     Abstract available


    June 2018
  41. KO KP, Kim SJ, Huzarski T, Gronwald J, et al
    The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.
    Int J Cancer. 2018;142:2263-2272.
    PubMed     Text format     Abstract available


    May 2018
  42. BIZZARO F, Falcetta F, D'Agostini E, Decio A, et al
    Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31596.
    PubMed     Text format     Abstract available


  43. SKOLD C, Bjorge T, Ekbom A, Engeland A, et al
    Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.
    Int J Cancer. 2018 May 8. doi: 10.1002/ijc.31581.
    PubMed     Text format     Abstract available


  44. HUANG RL, Chen HJ, Chen LY, Chao TK, et al
    Epigenetic loss of heparan sulfate 3-O-sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis.
    Int J Cancer. 2018 May 7. doi: 10.1002/ijc.31580.
    PubMed     Text format     Abstract available


    April 2018
  45. CHAN KK, Wong OG, Wong ES, Chan KK, et al
    Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31535.
    PubMed     Text format     Abstract available


  46. AGOSTINI A, Brunetti M, Davidson B, Trope CG, et al
    Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31418.
    PubMed     Text format     Abstract available


    March 2018
  47. PAPAEVANGELOU E, Almeida GS, Box C, deSouza NM, et al
    The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31392.
    PubMed     Text format     Abstract available


    February 2018
  48. KAAKS R, Fortner RT, Husing A, Barrdahl M, et al
    Tumor-associated auto-antibodies as early detection markers for ovarian cancer? A prospective evaluation.
    Int J Cancer. 2018 Feb 22. doi: 10.1002/ijc.31335.
    PubMed     Text format     Abstract available


  49. LIEW PL, Huang RL, Weng YC, Fang CL, et al
    Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.
    Int J Cancer. 2018 Feb 16. doi: 10.1002/ijc.31324.
    PubMed     Text format     Abstract available


    January 2018
  50. LOKKEGAARD ECL, Morch LS
    Tibolone and risk of gynecological hormone sensitive cancer.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31267.
    PubMed     Text format     Abstract available


    December 2017
  51. KHAIRALLAH AS, Genestie C, Auguste A, Leary A, et al
    Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
    Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31200.
    PubMed     Text format    


  52. REIMER D, Boesch M, Wolf D, Marth C, et al
    Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.
    Int J Cancer. 2017 Dec 1. doi: 10.1002/ijc.31186.
    PubMed     Text format     Abstract available


    November 2017
  53. FORTNER RT, Schock H, Le Cornet C, Husing A, et al
    Ovarian Cancer Early Detection by Circulating CA125 in the context of Anti-CA125 Autoantibody Levels: Results from the EPIC cohort.
    Int J Cancer. 2017 Nov 21. doi: 10.1002/ijc.31164.
    PubMed     Text format     Abstract available


  54. KIM J, Field A, Schultz KAP, Hill DA, et al
    The prevalence of DICER1 pathogenic variation in population databases.
    Int J Cancer. 2017;141:2030-2036.
    PubMed     Text format     Abstract available


  55. REGER MK, Zollinger TW, Liu Z, Jones JF, et al
    Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2017 Nov 8. doi: 10.1002/ijc.31095.
    PubMed     Text format     Abstract available


    October 2017
  56. FELIX AS, Brasky TM, Cohn DE, Mutch DG, et al
    Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
    Int J Cancer. 2017 Oct 24. doi: 10.1002/ijc.31127.
    PubMed     Text format     Abstract available


  57. MATSUO K, Shimada M, Yamaguchi S, Kanao H, et al
    Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31084.
    PubMed     Text format     Abstract available


    September 2017
  58. GAITSKELL K, Green J, Pirie K, Barnes I, et al
    Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31063.
    PubMed     Text format     Abstract available


  59. RICE MS, Rist PM, Winter AC, Kurth T, et al
    Migraine and invasive epithelial ovarian cancer risk in the Nurses' Health Study II and the Women's Health Study.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31062.
    PubMed     Text format     Abstract available


  60. JUNG S, Allen N, Arslan AA, Baglietto L, et al
    Anti-Mullerian Hormone and risk of ovarian cancer in nine cohorts.
    Int J Cancer. 2017 Sep 18. doi: 10.1002/ijc.31058.
    PubMed     Text format     Abstract available


    August 2017
  61. BABIC A, Harris HR, Vitonis AF, Titus LJ, et al
    Menstrual pain and risk of epithelial ovarian cancer: results from the Ovarian Cancer Association Consortium.
    Int J Cancer. 2017 Aug 22. doi: 10.1002/ijc.31010.
    PubMed     Text format     Abstract available


  62. WU YH, Huang YF, Chang TH, Chou CY, et al
    Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-kappaB-mediated IKKbeta expression.
    Int J Cancer. 2017 Aug 17. doi: 10.1002/ijc.30932.
    PubMed     Text format     Abstract available


  63. MORCH LS, Dehlendorff C, Baandrup L, Friis S, et al
    Use of antidepressants and risk of epithelial ovarian cancer.
    Int J Cancer. 2017 Aug 9. doi: 10.1002/ijc.30919.
    PubMed     Text format     Abstract available


    July 2017
  64. WU AH, Pearce CL, Lee A, Tseng C, et al
    Timing of births and oral contraceptive use influences ovarian cancer risk.
    Int J Cancer. 2017 Jul 27. doi: 10.1002/ijc.30910.
    PubMed     Text format     Abstract available


  65. GU F, Zhang H, Hyland PL, Berndt S, et al
    Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
    PubMed     Text format     Abstract available


  66. KRITSCH D, Hoffmann F, Steinbach D, Jansen L, et al
    Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30860.
    PubMed     Text format     Abstract available


    June 2017
  67. BIXEL K, Saini U, Bid HK, Fowler J, et al
    Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
    Int J Cancer. 2017 Jun 24. doi: 10.1002/ijc.30847.
    PubMed     Text format     Abstract available


  68. JAREID M, Licaj I, Olsen KS, Lund E, et al
    Does an epidemiological comparison support a common cellular lineage for similar subtypes of postmenopausal uterine and ovarian carcinoma? The Norwegian Women and Cancer Study.
    Int J Cancer. 2017 Jun 8. doi: 10.1002/ijc.30826.
    PubMed     Text format     Abstract available


    April 2017
  69. VERDOODT F, Kjaer Hansen M, Kjaer SK, Pottegard A, et al
    Statin use and mortality among ovarian cancer patients: A population-based cohort study.
    Int J Cancer. 2017 Apr 15. doi: 10.1002/ijc.30738.
    PubMed     Text format     Abstract available


    March 2017
  70. STALBERG K, Kjolhede P, Bjurberg M, Borgfeldt C, et al
    Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register study - On behalf of the Swedish gynecological cancer group (SweGCG).
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30707.
    PubMed     Text format     Abstract available


  71. COBURN SB, Bray F, Sherman ME, Trabert B, et al
    International patterns and trends in ovarian cancer incidence, overall and by histologic subtype.
    Int J Cancer. 2017 Mar 3. doi: 10.1002/ijc.30676.
    PubMed     Text format     Abstract available


    February 2017
  72. SHI T, Wang P, Xie C, Yin S, et al
    BRCA1 and BRCA2 mutations in ovarian cancer patients from China: Ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Int J Cancer. 2017 Feb 8. doi: 10.1002/ijc.30633.
    PubMed     Text format     Abstract available


    January 2017
  73. PRAESTEGAARD C, Jensen A, Jensen SM, Nielsen TS, et al
    Cigarette smoking is associated with adverse survival among women with ovarian cancer: results from a pooled analysis of 19 studies.
    Int J Cancer. 2017 Jan 7. doi: 10.1002/ijc.30600.
    PubMed     Text format     Abstract available


    December 2016
  74. TANG FH, Hsieh TH, Hsu CY, Lin HY, et al
    KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice.
    Int J Cancer. 2016 Dec 29. doi: 10.1002/ijc.30591.
    PubMed     Text format     Abstract available


  75. GARCIA-SANZ P, Trivino JC, Mota A, Perez Lopez M, et al
    Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
    Int J Cancer. 2016 Dec 20. doi: 10.1002/ijc.30573.
    PubMed     Text format     Abstract available


  76. JONES NL, Xiu J, Chatterjee-Paer S, Buckley de Meritens A, et al
    Distinct molecular landscapes between endometrioid and non-endometrioid uterine carcinomas.
    Int J Cancer. 2016 Dec 1. doi: 10.1002/ijc.30537.
    PubMed     Text format     Abstract available


    October 2016
  77. TRABERT B, Eldridge RC, Pfeiffer RM, Shiels MS, et al
    Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
    Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30478.
    PubMed     Text format     Abstract available


  78. PERES LC, Bandera EV, Qin B, Guertin KA, et al
    Dietary Inflammatory Index and Risk of Epithelial Ovarian Cancer in African American Women.
    Int J Cancer. 2016 Oct 11. doi: 10.1002/ijc.30467.
    PubMed     Text format     Abstract available


    September 2016
  79. HARRIS HR, Titus LJ, Cramer DW, Terry KL, et al
    Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.
    Int J Cancer. 2016 Sep 26. doi: 10.1002/ijc.30441.
    PubMed     Text format     Abstract available


  80. KRAUS C, Hoyer J, Vasileiou G, Wunderle M, et al
    Gene panel sequencing in familial Breast/Ovarian Cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30428.
    PubMed     Text format     Abstract available


    August 2016
  81. MARSHALL AD, van Geldermalsen M, Otte NJ, Anderson L, et al
    LAT1 is a Putative Therapeutic Target in Endometrioid Endometrial Carcinoma.
    Int J Cancer. 2016 Aug 3. doi: 10.1002/ijc.30371.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: